On Saturday, August 13, 2005 from 11:00 am - 2:00 pm at 12140 Vintage Lane, Glen Ellen, California, the University of Northern California (UNC) will be hosting a wine and food pairing as an opportunity for information gathering and networking for professionals in the technology and medical professions. Dr. Y. King Liu, Founder and Chairman of Board of Directors of UNC, will be present to discuss its new Executive MBA Program in Biomedicine. Also in attendance will be another UNC Board Member, Mr. Howard Leonhardt, Founder and CEO of Bioheart, Inc. (http://www.bioheartinc.com). Mr. Leonhardt holds a dozen medical patents, including the famous Talent stent. He was formerly with Arterial Vascular Engineering and Medtronics. Mr. Leonhardt will discuss his second major startup and industry-specific educational programs to support the success of new medical technologies.
For those interested in attending, call Tracy Li at 707-765-6400 or e-mail admits@uncm.edu to RSVP.
About University of Northern California
UNC’s colleges include Engineering, Business Administration, and Language & Linguistics. UNC aspires to become a premiere engineering and technological university with substantial programs in the liberal arts and sciences. Its special focus is on programs in biological technology including the B.S. and M.S. degrees in Optical & Photonic Engineering, M.S. in Systems Engineering (emphasis: embedded software), and the B.E., M.S., & Ph.D. degrees in Biomedical Engineering. UNC also offers bachelor’s degrees in Languages and B.A. and M.A. in Applied Linguistics (M.A. in TESOL), as well as master’s degree in Business Administration (MBA). Currently, the University of Northern California is accepting applications for its new Executive MBA in Biomedicine program which is designed to meet the needs of busy biotech managers, engineers, and medical professionals. The program will be delivered in a “blended format” where students spend some time on campus and the rest of the work is done via the Internet. MBA classes start August 27, 2005. Students with appropriate undergraduate preparation and work experience will be considered for acceptance into the program. Faculty for the program has been selected for their teaching excellence, industry experience, and international orientation.
For an information packet, contact: Admissions Office University of Northern California 1304 South Point Blvd., Suite 220 Petaluma, CA 94954 e-mail: admits@uncm.edu Tele: 707-765-6400 FAX: 707-769-8600
About Bioheart, Inc.
Bioheart, Inc. is focused on the discovery, development, and commercialization of cell-based therapy products for the treatment of cardiovascular diseases such as congestive heart failure (“CHF”) secondary to myocardial infarction (“MI”) and cardiovascular electrical abnormalities. The Company believes that its products hold the potential to revolutionize the treatment of cardiovascular diseases and become a new standard of care by offering treatments that improve cardiac function, are more cost-effective and are lower-risk than the current alternatives, which include heart transplantation, biventricular pacing, ventricular assist devices and certain drug therapies.